Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial

Table 4 Multivariate logistic regression analysis of factors associated with the development of grade ≥ 2 hematologic toxicity

Parameter	Odds ratio	p	95CI
LSS
V10	1.07	< 0.01^a	1.03,1.11
Mean dose	1.001	< 0.01^a	1.000,1.002
PB
V10	1.04	0.06	0.99,1.08
V20	1.03	0.06	0.99,1.05
V40	1.09	0.03^a	1.03,1.16
Mean dose	1.001	0.07	1.000,1.002
LSS MARROW
V10	1.15	< 0.01^a	1.05,1.24
V20	1.06	< 0.01^a	1.02,1.09
V40	1.02	0.01^a	1.00,1.04
Mean dose	1.001	< 0.01^a	1.000,1.002
PB MARROW
V10	1.04	0.06	0.99,1.08
V20	1.03	0.06	0.99,1.05
V40	1.09	< 0.01^a	1.03,1.16
Mean dose	1.001	0.07	1.000,1.002
HIP MARROW
V10	1.03	0.08	0.99,1.07
V20	1.02	0.17	0.99,1.05
V40	1.06	0.06	0.99,1.13
Mean dose	1.001	0.06	1.000,1.002

Each dosimetric variable was combined with all clinical variables (clinical stage, ECOG score, BMI, age, pathology and comorbidity). Odds ratio correspond to 1% increase in factors approximately increased or decreased relative odds of HT2+. CI onfidence interval; other abbreviations as in Tables 2
^aStatistically significant

ISSN: 1748-717X